Trials / Completed
CompletedNCT06173037
RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer
A Multicenter, Single-arm, Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of RC88 Monotherapy in Platinum-resistant Recurrent Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 43 (actual)
- Sponsor
- RemeGen Co., Ltd. · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of RC88 monotherapy in subjects with Platinum-Resistant Recurrent Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RC88 | 2.0 mg/kg Q3W IV |
Timeline
- Start date
- 2024-01-19
- Primary completion
- 2025-12-31
- Completion
- 2025-12-31
- First posted
- 2023-12-15
- Last updated
- 2026-01-07
Locations
30 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06173037. Inclusion in this directory is not an endorsement.